Human trials of cancer drug PAC-1 continue with new investment
May 24, 2016
Clinical trials of the anti-cancer agent PAC-1 are continuing to expand, thanks to a $7 million angel investment from an anonymous contributor who originally invested $4 million to help get the compound this far in the drug-approval pipeline.
May 24, 2016
